Addex Therapeutics (Switzerland) Today

ADXN Stock  CHF 0.06  0.0002  0.35%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 21

 
High
 
Low
Low
Addex Therapeutics is selling for under 0.0566 as of the 26th of November 2024; that is 0.35 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0564. Addex Therapeutics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Addex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of August 2024 and ending today, the 26th of November 2024. Click here to learn more.
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. The company has 115.35 M outstanding shares. More on Addex Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Addex Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Addex Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Addex Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Business Concentrationnull, null, Biotechnology, Healthcare (View all Sectors)
Addex Therapeutics (ADXN) is traded on SIX Swiss Exchange in Switzerland and employs 26 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Addex Therapeutics's market, we take the total number of its shares issued and multiply it by Addex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Addex Therapeutics operates under null sector and is part of null industry. The entity has 115.35 M outstanding shares. Addex Therapeutics has accumulated about 20.48 M in cash with (14.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Addex Therapeutics Probability Of Bankruptcy
Ownership Allocation
Addex Therapeutics holds a total of 115.35 Million outstanding shares. Addex Therapeutics shows 8.96 percent of its outstanding shares held by insiders and 9.31 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Addex Ownership Details

Addex Therapeutics Risk Profiles

Although Addex Therapeutics' alpha and beta are two of the key measurements used to evaluate Addex Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Addex Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Addex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run USA ETFs Now

   

USA ETFs

Find actively traded Exchange Traded Funds (ETF) in USA
All  Next Launch Module

Addex Therapeutics Corporate Management

Elected by the shareholders, the Addex Therapeutics' board of directors comprises two types of representatives: Addex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Addex. The board's role is to monitor Addex Therapeutics' management team and ensure that shareholders' interests are well served. Addex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Addex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

Additional Tools for Addex Stock Analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.